Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009508 | 0.88 | NTRK1 (0.51) | NTRK1CSNK2A1KDM4ESTAT3HIF1A | |
| SCHEMBL4007991 | 0.85 | CSNK2A1 (0.54) | NTRK1CSNK2A1CDK2JAK2DYRK3 | |
| SCHEMBL4013510 | 0.84 | HSD11B1 (0.41) | NTRK1CSNK2A1KDM4ESTAT3HIF1A | |
| SCHEMBL4008960 | 0.83 | HSD11B1 (0.37) | NTRK1CSNK2A1ALDH1A1LMNAHSD11B1 | |
| SCHEMBL4010492 | 0.82 | HSD11B1 (0.36) | NTRK1CSNK2A1ALDH1A1LMNAHTT | |
| SCHEMBL4010520 | 0.82 | HSD11B1 (0.36) | NTRK1CSNK2A1ALDH1A1LMNAHTT | |
| SCHEMBL4013445 | 0.81 | HPGD (0.45) | NTRK1CSNK2A1KDM4EALDH1A1CDK2 | |
| SCHEMBL4008425 | 0.81 | PRKAG1 (0.40) | NTRK1CSNK2A1KDM4ESTAT3HIF1A | |
| SCHEMBL4010189 | 0.80 | NTRK1 (0.39) | NTRK1CSNK2A1ALDH1A1LMNAHTT | |
| SCHEMBL6554348 | 0.79 | CSNK2A1 (0.39) | NTRK1CSNK2A1CDK2ATRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NTRK1 1342/4885CSNK2A1 129/4885KDM4E 980/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NTRK1 1376/4885CSNK2A1 111/4885KDM4E 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.